Magrolimab

Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab can block the "don't eat me" signal of CD47, thereby promoting macrophage mediated phagocytosis. Magrolimab has antitumor activity in malignant bone tumors and breast cancer[1][2][3].

Product Specifications

CAS Number

[2169232-81-7]

Product Name Alternative

Hu5F9-G4

UNSPSC

12352203

Target

CD47

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/magrolimab.html

Purity

99.92

Solubility

H2O

Smiles

[Magrolimab]

Molecular Weight

(145.73 kDa)

References & Citations

[1]Luo W, et al. A humanized orthotopic mouse model for preclinical evaluation of immunotherapy in Ewing sarcoma. Front Immunol. 2023 Oct 6;14:1277987. |[2]Upton R, et al. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. Proc Natl Acad Sci U S A. 2021 Jul 20;118 (29) :e2026849118.|[3]Liu Y, et al. PARP inhibition synergizes with CD47 blockade to promote phagocytosis by tumor-associated macrophages in homologous recombination-proficient tumors. Life Sci. 2023 Aug 1;326:121790.